Fundamentals-
1)Excellent company with excellent fundamentals.
2)Expanding at very high rate. around 20% YoY basis.
3)Excellent numbers like operating profit, very good valuation with peers within the sector.
4)Awesome sales and profit figures.
5) Recently entered into the the medicines for Oncology
6)One of the very few pharmaceutical companies to manufacture oncology medicines so will enjoy the special premium.
4)Company is reducing debt drastically.
Keynote-->Its a good stock that can be accumulated at every dip.It seems to be a bull stock.
CMP-814(23rd Feb'2017)
1st target-1000(6 months)
Disclaimer : I am a private trader who is just expressing his views. These are just my opinions and i am not giving any kind of free or paid calls. I am using this platform to share my knowledge and learn from other's knowledge. I might be/might not be invested in my opinions.
Note : Please like/comment to show your support if my analysis helps you.
1)Excellent company with excellent fundamentals.
2)Expanding at very high rate. around 20% YoY basis.
3)Excellent numbers like operating profit, very good valuation with peers within the sector.
4)Awesome sales and profit figures.
5) Recently entered into the the medicines for Oncology
6)One of the very few pharmaceutical companies to manufacture oncology medicines so will enjoy the special premium.
4)Company is reducing debt drastically.
Keynote-->Its a good stock that can be accumulated at every dip.It seems to be a bull stock.
CMP-814(23rd Feb'2017)
1st target-1000(6 months)
Disclaimer : I am a private trader who is just expressing his views. These are just my opinions and i am not giving any kind of free or paid calls. I am using this platform to share my knowledge and learn from other's knowledge. I might be/might not be invested in my opinions.
Note : Please like/comment to show your support if my analysis helps you.
ความคิดเห็น:
Target reached!
การซื้อขายยังคงดำเนินอยู่:
Accumulate for more gains!
Target 1500 in 12 months
CMP-1072(11th June'2017)
Target 1500 in 12 months
CMP-1072(11th June'2017)